Testing effectiveness (Phase 2)Not Yet RecruitingNCT07646821
What this trial is testing
A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (≥ 10% Blasts) With TP53 Mutations
Who this might be right for
RopeginterferonAlfa-2bAzacitidine+1 more
M.D. Anderson Cancer Center 30